|
| Press Releases |
|
 |
|
| Friday, August 15, 2025 |
|
|
OrbusNeich Records Growth in 2025 Interim Results, Revenue and Net Profit Reach US$83.6 Million and US$19.8 Million Respectively |
| OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its interim results for the six months ended June 30, 2025 (the 'Period'), reporting growth in both revenue and net profit despite an uncertain macroeconomic landscape. more info >> |
|
|
業聚醫療2025年中期業績收入及純利雙雙增長 分別達8,360萬美元及1,980萬美元 |
| 專營經皮冠狀動脈介入治療（PCI）及經皮腔內血管成形術（PTA）手術介入器械的全球醫療器械製造公司業聚醫療集團控股有限公司（「業聚醫療」或「集團」；股份代號：6929）今天宣佈截至2025年6月30日止六個月(「報告期」)的中期業績。儘管宏觀經濟環境未見明朗，集團的收入及純利仍雙雙錄得增長。 more info >> |
|
|
业聚医疗2025年中期业绩收入及纯利双双增长 分别达8,360万美元及1,980万美元 |
| 专营经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）手术介入器械的全球医疗器械制造公司业聚医疗集团控股有限公司（"业聚医疗"或"集团"；股份代号：6929）今天宣布截至2025年6月30日止六个月("报告期")的中期业绩。尽管宏观经济环境未见明朗，集团的收入及纯利仍双双录得增长。 more info >> |
|
| Friday, March 7, 2025 |
|
|
OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million |
| OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its annual results for the year ended December 31, 2024 (the 'Year'), reporting record-high revenue and healthy net profit despite the challenging business landscape. more info >> |
|
|
業聚醫療連續四年實現收入增長 達1.64億美元創新高 純利達3,970萬美元 建議派發末期股息每股10港仙 |
| 專營經皮冠狀動脈介入治療（PCI）及經皮腔內血管成形術（PTA）手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司（「業聚醫療」或「集團」；股份代號：6929）今天宣佈截至截至2024年12月31日止年度（「年度」）的全年業績。 more info >> |
|
|
业聚医疗连续四年实现收入增长 达1.64亿美元创新高 纯利达3,970万美元 建议派发末期股息每股10港仙 |
| 专营经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）手术介入器械的全球主要医疗器械制造商业聚医疗集团控股有限公司（“业聚医疗”或“集团”；股份代号：6929）今天宣布截至截至2024年12月31日止年度（“年度”）的全年业绩。 more info >> |
|
| Friday, August 16, 2024 |
|
|
OrbusNeich Records Net Profit of US$18.8 Million for the First Half of 2024 |
| OrbusNeich Medical Group Holdings Limited ('OrbusNeich' or the 'Group'; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention ('PCI') and percutaneous transluminal angioplasty ('PTA') procedures, today announced its interim results for the six months ended June 30, 2024 (the 'Reporting Period), with revenue and profit for the period attributable to owners of the Company maintained at US$78.9 million and US$18.8 million respectively despite various market challenges. more info >> |
|
|
业聚医疗2024年上半年纯利达1,880万美元 |
| 专营经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）手术介入器械的全球主要医疗器械制造商业聚医疗集团控股有限公司（「业聚医疗」或「集团」；股份代号：6929）今天宣布截至2024年6月30日止六个月(「报告期」)的中期业绩。 more info >> |
|
|
業聚醫療2024年上半年純利達1,880萬美元 |
| 專營經皮冠狀動脈介入治療（PCI）及經皮腔內血管成形術（PTA）手術介入器械的全球主要醫療器械製造商業聚醫療集團控股有限公司（「業聚醫療」或「集團」；股份代號：6929）今天宣佈截至2024年6月30日止六個月(「報告期」)的中期業績。 more info >> |
|
| Wednesday, April 24, 2024 |
|
|
业聚医疗合资企业在中国内地启动TricValve临床试验 |
| more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
周大福人壽支持《財政預算案》有關跨境安老、落實《香港可持續披露準則》以及推動體育普及化、盛事化等措施
Feb 25, 2026 18:07 HKT/SGT
|
|
|
HKTDC welcomes the 2026-27 Budget
Feb 25, 2026 17:29 HKT/SGT
|
|
|
維昇藥業（2561.HK）維臻高(R)獲批：重長效生長激素王者登場 重構百億市場的商業天花板
Feb 25, 2026 14:58 HKT/SGT
|
|
|
Shoucheng Holdings (00697.HK) Sees Long-Term International Capital Rotation as Robotics Portfolio Enters Harvest Phase
Feb 25, 2026 12:23 HKT/SGT
|
|
|
首程控股（00697.HK）迎來國際長線接盤 機器人產業生態進入價值收割期
Feb 25, 2026 12:23 HKT/SGT
|
|
|
首程控股（00697.HK）迎来国际长线接盘 机器人产业生态进入价值收割期
Feb 25, 2026 12:23 HKT/SGT
|
|
|
ベイシアのスーパーマーケット内の冷蔵・冷凍庫の温度点検・記録業務を富士通のIoT可視化ソリューションにより自動化
Feb 25, 2026 12:00: JST
|
|
|
Beisia Automates Supermarket Refrigerator Temperature Monitoring and Recording with Fujitsu's IoT Visualization Solution
Feb 25, 2026 12:00 JST
|
|
|
國泰君安國際獲批使用SIMM 衍生品風險管理接軌國際標準
Feb 25, 2026 10:34 HKT/SGT
|
|
|
国泰君安国际获批使用SIMM 衍生品风险管理接轨国际标准
Feb 25, 2026 10:34 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 22:30: JST
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 21:30 HKT/SGT
|
|
|
TANAKA to Provide Medals for the Tokyo Marathon 2026 That Represent All the Participants in the Event with Woven Lines
Feb 24, 2026 22:00 JST
|
|
|
康哲藥業（867.HK/8A8.SG）：創新藥磷酸蘆可替尼乳膏增加特應性皮炎（AD）適應症中國上市許可申請獲受理並獲納入優先審評
Feb 24, 2026 20:31 HKT/SGT
|
|
|
康哲药业（867.HK/8A8.SG）：创新药磷酸芦可替尼乳膏增加特应性皮炎（AD）适应症中国上市许可申请获受理并获纳入优先审评
Feb 24, 2026 20:19 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
